Christopher Raymond
Stock Analyst at Raymond James
(2.66)
# 2,896
Out of 5,004 analysts
876
Total ratings
43.7%
Success rate
0.9%
Average return
Main Sectors:
Stocks Rated by Christopher Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMGN Amgen | Maintained: Hold | n/a | $406.09 | - | 79 | Sep 25, 2026 | |
| TYRA Tyra Biosciences | Maintained: Buy | $50 | $23.23 | +115.24% | 9 | Sep 24, 2026 | |
| BHVN Biohaven | Reiterated: Buy | n/a | $13.67 | - | 24 | Sep 10, 2026 | |
| ALMS Alumis | Reiterated: Buy | n/a | $7.44 | - | 3 | Sep 2, 2026 | |
| SGP SpyGlass Pharma | Initiated Coverage: Buy | $39 | $28.16 | +38.49% | 1 | Aug 14, 2026 | |
| SION Sionna Therapeutics | Downgraded: Hold | n/a | $5.51 | - | 1 | Aug 10, 2026 | |
| ARDX Ardelyx | Reiterated: Buy | $19 → $15 | $3.48 | +331.03% | 42 | Aug 7, 2026 | |
| BMRN BioMarin Pharmaceutical | Reiterated: Buy | $105 | $62.21 | +68.78% | 87 | Aug 7, 2026 | |
| CLYM Climb Bio | Reiterated: Buy | n/a | $12.52 | - | 3 | Jun 24, 2026 | |
| AKTS Aktis Oncology | Initiated Coverage: Buy | $40 | $19.72 | +102.84% | 1 | Jun 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $723 → $870 | $801.82 | +8.50% | 114 | Jan 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $60 | $31.41 | +91.02% | 20 | Jan 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $3.52 | +610.23% | 2 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $47 | $5.61 | +737.79% | 1 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 | $4.91 | +164.77% | 6 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $142 → $123 | $89.38 | +37.61% | 5 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $26 → $29 | $11.75 | +146.81% | 11 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $23 | $3.12 | n/a | 14 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $533 → $401 | $516.34 | n/a | 26 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 | $5.26 | n/a | 6 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $140 | $14.88 | n/a | 58 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $20 → $4 | $9.56 | n/a | 6 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $42 | $94.13 | n/a | 5 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $220 → $227 | $265.08 | n/a | 84 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $75 | $1.75 | n/a | 21 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $307 → $315 | $227.53 | n/a | 91 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $56 | $34.19 | n/a | 11 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $20 | $8.57 | n/a | 19 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $10 | $0.0002 | n/a | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $21 → $8 | $1.47 | n/a | 24 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $0.9326 | n/a | 22 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $600 | $945.82 | n/a | 1 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $58 | $43.93 | n/a | 1 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $22 | $59.83 | n/a | 1 | Jul 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $1.38 | n/a | 1 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $28 | $1.79 | n/a | 5 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $28 | $30.16 | n/a | 1 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $3 | $7.42 | n/a | 6 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $75 → $30 | $8.02 | n/a | 5 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $7 → $6 | $1.25 | n/a | 20 | May 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $48.13 | n/a | 12 | Apr 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $8.61 | n/a | 4 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $39.01 | n/a | 1 | Apr 18, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.54 | n/a | 6 | Aug 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $42 → $101 | - | n/a | 2 | Mar 31, 2015 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.002 | n/a | 6 | Mar 19, 2013 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $3 → $6 | $2.60 | n/a | 3 | Feb 29, 2012 |
Amgen
Sep 25, 2026
Maintained: Hold
Price Target: n/a
Current: $406.09
Upside: -
Tyra Biosciences
Sep 24, 2026
Maintained: Buy
Price Target: $50
Current: $23.23
Upside: +115.24%
Biohaven
Sep 10, 2026
Reiterated: Buy
Price Target: n/a
Current: $13.67
Upside: -
Alumis
Sep 2, 2026
Reiterated: Buy
Price Target: n/a
Current: $7.44
Upside: -
SpyGlass Pharma
Aug 14, 2026
Initiated Coverage: Buy
Price Target: $39
Current: $28.16
Upside: +38.49%
Sionna Therapeutics
Aug 10, 2026
Downgraded: Hold
Price Target: n/a
Current: $5.51
Upside: -
Ardelyx
Aug 7, 2026
Reiterated: Buy
Price Target: $19 → $15
Current: $3.48
Upside: +331.03%
BioMarin Pharmaceutical
Aug 7, 2026
Reiterated: Buy
Price Target: $105
Current: $62.21
Upside: +68.78%
Climb Bio
Jun 24, 2026
Reiterated: Buy
Price Target: n/a
Current: $12.52
Upside: -
Aktis Oncology
Jun 16, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $19.72
Upside: +102.84%
Jan 30, 2026
Reiterated: Buy
Price Target: $723 → $870
Current: $801.82
Upside: +8.50%
Jan 26, 2026
Reiterated: Buy
Price Target: $60
Current: $31.41
Upside: +91.02%
Jan 13, 2026
Reiterated: Buy
Price Target: $25
Current: $3.52
Upside: +610.23%
Dec 2, 2025
Initiated Coverage: Buy
Price Target: $47
Current: $5.61
Upside: +737.79%
Nov 25, 2025
Reiterated: Buy
Price Target: $13
Current: $4.91
Upside: +164.77%
Nov 14, 2025
Reiterated: Buy
Price Target: $142 → $123
Current: $89.38
Upside: +37.61%
Oct 20, 2025
Initiated Coverage: Buy
Price Target: $26 → $29
Current: $11.75
Upside: +146.81%
Sep 16, 2025
Reiterated: Buy
Price Target: $23
Current: $3.12
Upside: n/a
Sep 2, 2025
Initiated Coverage: Hold
Price Target: $533 → $401
Current: $516.34
Upside: n/a
Feb 18, 2025
Reiterated: Buy
Price Target: $13
Current: $5.26
Upside: n/a
Feb 14, 2025
Reiterated: Buy
Price Target: $140
Current: $14.88
Upside: n/a
Feb 11, 2025
Downgraded: Hold
Price Target: $20 → $4
Current: $9.56
Upside: n/a
Feb 10, 2025
Reiterated: Buy
Price Target: $42
Current: $94.13
Upside: n/a
Jan 27, 2025
Rated: Buy
Price Target: $220 → $227
Current: $265.08
Upside: n/a
Jan 27, 2025
Rated: Buy
Price Target: $75
Current: $1.75
Upside: n/a
Oct 30, 2024
Reiterated: Buy
Price Target: $307 → $315
Current: $227.53
Upside: n/a
Oct 23, 2024
Rated: Buy
Price Target: $56
Current: $34.19
Upside: n/a
Oct 23, 2024
Rated: Buy
Price Target: $20
Current: $8.57
Upside: n/a
Sep 16, 2024
Rated: Buy
Price Target: $10
Current: $0.0002
Upside: n/a
Aug 9, 2024
Rated: Buy
Price Target: $21 → $8
Current: $1.47
Upside: n/a
Oct 25, 2023
Reiterated: Buy
Price Target: $4
Current: $0.9326
Upside: n/a
Oct 25, 2023
Reiterated: Buy
Price Target: $600
Current: $945.82
Upside: n/a
Oct 25, 2023
Reiterated: Buy
Price Target: $58
Current: $43.93
Upside: n/a
Jul 24, 2023
Rated: Hold
Price Target: $22
Current: $59.83
Upside: n/a
Apr 25, 2023
Reiterated: Buy
Price Target: $14
Current: $1.38
Upside: n/a
Nov 22, 2022
Reiterated: Hold
Price Target: $28
Current: $1.79
Upside: n/a
Jul 25, 2022
Initiated Coverage: Buy
Price Target: $28
Current: $30.16
Upside: n/a
May 23, 2022
Reiterated: Buy
Price Target: $3
Current: $7.42
Upside: n/a
May 18, 2022
Reiterated: Hold
Price Target: $75 → $30
Current: $8.02
Upside: n/a
May 11, 2021
Reiterated: Hold
Price Target: $7 → $6
Current: $1.25
Upside: n/a
Apr 13, 2021
Reiterated: Buy
Price Target: $8
Current: $48.13
Upside: n/a
Mar 27, 2020
Reiterated: Buy
Price Target: n/a
Current: $8.61
Upside: n/a
Apr 18, 2019
Reiterated: Hold
Price Target: n/a
Current: $39.01
Upside: n/a
Aug 7, 2017
Rated: Hold
Price Target: n/a
Current: $3.54
Upside: n/a
Mar 31, 2015
Downgraded: Hold
Price Target: $42 → $101
Current: -
Upside: n/a
Mar 19, 2013
Reiterated: Hold
Price Target: n/a
Current: $0.002
Upside: n/a
Feb 29, 2012
Upgraded: Buy
Price Target: $3 → $6
Current: $2.60
Upside: n/a